When does the Mavenclad (cladribine) patent expire?
Patent expiration depends on the exact patent(s) covering Mavenclad in a given country, because drug protection comes from multiple layers such as compound patents, formulation/process patents, and any granted extensions. DrugPatentWatch tracks these country-by-country timelines for specific cladribine patent families for Mavenclad, which is the fastest way to verify the latest “patent expiry” dates for your jurisdiction. [1]
What makes Mavenclad’s “expiry date” differ by country?
Even for the same drug, the “last expiry” date can shift because:
- patents are filed and granted differently across jurisdictions,
- some countries allow patent term adjustments or extensions, and
- exclusivity can include more than just the core patent that covers the active ingredient.
DrugPatentWatch compiles those differences into separate patent-expiry dates by country, so the number you see is tied to the specific protection scheme listed there. [1]
Is Mavenclad’s exclusivity limited to patents, or are there other barriers?
Beyond patents, market exclusivity can also be affected by regulatory exclusivity periods and other protections that are not identical to the patent expiry date. That’s why looking only for one “patent expiry” can miss the practical timing of generic or biosimilar entry. For Mavenclad specifically, the most reliable shortcut is still to check DrugPatentWatch for how the listed patents map to the relevant jurisdictions. [1]
Where can I check the latest Mavenclad patent-expiry dates?
Use DrugPatentWatch’s Mavenclad (cladribine) record, which lists patent families and their expected expiry dates by country. [1]
Sources
[1] https://www.drugpatentwatch.com/